{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:18:27Z","timestamp":1771474707461,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The opioid epidemic worsened during the coronavirus disease 2019 (COVID-19) pandemic. Synthetic opioids (primarily fentanyl) comprise the most common drugs involved in overdose (OD) death. A vaccine that blocks fentanyl from reaching the brain to prevent OD is under development, and insight is needed into its acceptability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using a semi-structured interview guide, persons with opioid use disorder (OUD), family, professionals, and the public were interviewed about attitudes and concerns regarding a fentanyl vaccine. Reactions to fictional clinical vignettes of persons at risk of OUD because of pain and\/or substance use histories were collected, analyzed, and quantified for favorability. Interviews were transcribed, coded, and analyzed thematically.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among N\u2009=\u200964 participants, (70.3% female, average age 32.4 years), attitudes were favorable toward a fentanyl vaccine, with preference for lifelong durability (76% of n\u2009=\u200955 asked). Perceived benefits centered on the potential for a life-saving intervention, suffering averted, healthcare dollars saved, and the utility of a passive harm reduction strategy. Concerns centered on uncertainty regarding vaccine safety, questions about efficacy, worry about implications for future pain management, stigma, and need for supportive counseling and guidance to personalize decision making. Reactions to vignettes revealed complex attitudes toward fentanyl vaccination when considering recipient age, health history, and future risks for addiction and pain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Positive responses to a fentanyl vaccine were found along with appreciation for the complexity of a vaccine strategy to prevent OD in the setting of pain and uncertain durability. Further research is needed to elucidate operational, ethical, and communications strategies to advance the model.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciac344","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T04:01:35Z","timestamp":1651809695000},"page":"S98-S109","source":"Crossref","is-referenced-by-count":8,"title":["Acceptability of a Fentanyl Vaccine to Prevent Opioid Overdose and Need for Personalized Decision-Making"],"prefix":"10.1093","volume":"75","author":[{"given":"Elissa R","family":"Weitzman","sequence":"first","affiliation":[{"name":"Division of Adolescent\/Young Adult Medicine, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"},{"name":"Computational Health Informatics Program, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"},{"name":"Department of Pediatrics, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Kossowsky","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Harvard Medical School , Boston, Massachusetts , USA"},{"name":"Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M","family":"Blakemore","sequence":"additional","affiliation":[{"name":"Division of Adolescent\/Young Adult Medicine, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachele","family":"Cox","sequence":"additional","affiliation":[{"name":"Division of Adolescent\/Young Adult Medicine, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Dowling","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Harvard Medical School , Boston, Massachusetts , USA"},{"name":"Precision Vaccines Program, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"},{"name":"Division of Infectious Diseases, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Harvard Medical School , Boston, Massachusetts , USA"},{"name":"Precision Vaccines Program, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"},{"name":"Division of Infectious Diseases, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"},{"name":"Broad Institute of MIT & Harvard , Cambridge, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma W","family":"Needles","sequence":"additional","affiliation":[{"name":"Adolescent Substance Use and Addiction Program, Division of Developmental Medicine, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Harvard Medical School , Boston, Massachusetts , USA"},{"name":"Adolescent Substance Use and Addiction Program, Division of Developmental Medicine, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"2022081503572654500_ciac344-B1","article-title":"Drug Overdose | Drug Policy Alliance","author":"Drug Policy Alliance","year":"2020"},{"key":"2022081503572654500_ciac344-B2","first-page":"1","volume-title":"The opioid crisis and life expectancy in the US","author":"Lozano","year":"2020"},{"key":"2022081503572654500_ciac344-B3","year":"2021"},{"key":"2022081503572654500_ciac344-B4"},{"key":"2022081503572654500_ciac344-B5","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010\u20132016","volume":"319","author":"Jones","year":"2018","journal-title":"JAMA"},{"key":"2022081503572654500_ciac344-B6","article-title":"Overdose Death Rates | National Institute on Drug Abuse (NIDA). 2019. Available at:","author":"NIDA"},{"key":"2022081503572654500_ciac344-B7"},{"key":"2022081503572654500_ciac344-B8","article-title":"CDC\u2019s Response to the Opioid Overdose Epidemic. 2019. Available at:","author":"Center for Disease Control and Prevention"},{"key":"2022081503572654500_ciac344-B9","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41390-020-01112-y","article-title":"The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems","volume":"89","author":"Soni","year":"2021","journal-title":"Pediatr Res"},{"key":"2022081503572654500_ciac344-B10","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1517\/13543784.16.11.1775","article-title":"Vaccination against nicotine: an emerging therapy for tobacco dependence","volume":"16","author":"Maurer","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"2022081503572654500_ciac344-B11","first-page":"200","article-title":"Vaccines against nicotine","volume":"5","author":"Cerny","year":"2009","journal-title":"HumanVaccines"},{"key":"2022081503572654500_ciac344-B12","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.1016\/j.vaccine.2015.09.079","article-title":"Is immunotherapy an opportunity for effective treatment of drug addiction?","volume":"33","author":"Zalewska-Kaszubska","year":"2015","journal-title":"Vaccine"},{"key":"2022081503572654500_ciac344-B13","doi-asserted-by":"crossref","first-page":"108225","DOI":"10.1016\/j.neuropharm.2020.108225","article-title":"Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models","volume":"178","author":"Smith","year":"2020","journal-title":"Neuropharmacology"},{"key":"2022081503572654500_ciac344-B14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nyas.14329","article-title":"Current status of immunotherapies for addiction","volume":"1489","author":"Xu","year":"2020","journal-title":"Ann N Y Acad Sci"},{"key":"2022081503572654500_ciac344-B15","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.tips.2018.08.001","article-title":"Immunopharmacotherapies for treating opioid use disorder","volume":"39","author":"Banks","year":"2018","journal-title":"Trends in Pharmacol Sci"},{"key":"2022081503572654500_ciac344-B16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1037\/amp0000713","article-title":"Guest editorial: Psychologists aim to HEAL the opioid and pain crises","volume":"75","author":"Wandner","year":"2020","journal-title":"Am Psychol"},{"key":"2022081503572654500_ciac344-B17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MOP.0000000000000868","article-title":"Toward precision adjuvants: optimizing science and safety","volume":"32","author":"Nanishi","year":"2020","journal-title":"Curr Opin Pediatr"},{"key":"2022081503572654500_ciac344-B18","doi-asserted-by":"crossref","first-page":"e1002922","DOI":"10.1371\/journal.pmed.1002922","article-title":"Prescription opioid use and misuse among adolescents and young adults in the United States: A national survey study","volume":"16","author":"Hudgins","year":"2019","journal-title":"PLoS Med"},{"key":"2022081503572654500_ciac344-B19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.15288\/jsad.2020.81.484","article-title":"Nonmedical use of prescription opioids, heroin use, injection drug use, and overdose mortality in U.S. adolescents","volume":"81","author":"Bohm","year":"2020","journal-title":"J Stud Alcohol Drugs"},{"key":"2022081503572654500_ciac344-B20","article-title":"Marijuana use at historic high among college-aged adults in 2020","author":"NIDA"},{"key":"2022081503572654500_ciac344-B21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/164_2018_110","article-title":"Fatal poisonings associated with new psychoactive substances","volume":"252","author":"Kronstrand","year":"2018","journal-title":"Handb Exp Pharmacol"},{"key":"2022081503572654500_ciac344-B22","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.15585\/mmwr.mm6736a2","article-title":"Prevalence of chronic pain and high-impact chronic pain among adults\u2014United States, 2016","volume":"67","author":"Dahlhamer","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022081503572654500_ciac344-B23","first-page":"1","article-title":"Prescription opioid use among adults with chronic pain: United States, 2019","volume":"162","author":"Dahlhamer","year":"2021","journal-title":"Natl Health Stat Report"},{"key":"2022081503572654500_ciac344-B24","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","article-title":"Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis","volume":"156","author":"Vowles","year":"2015","journal-title":"Pain"},{"key":"2022081503572654500_ciac344-B25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1037\/a0022870","article-title":"Behavioral and emotional regulation and adolescent substance use problems: a test of moderation effects in a dual-process model","volume":"25","author":"Wills","year":"2011","journal-title":"Psychol Addict Behav"},{"key":"2022081503572654500_ciac344-B26","doi-asserted-by":"crossref","first-page":"107523","DOI":"10.1016\/j.drugalcdep.2019.06.025","article-title":"Patient perspectives on a harm reduction-oriented addiction medicine consultation team implemented in a large acute care hospital","volume":"204","author":"Hyshka","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2022081503572654500_ciac344-B27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.drugpo.2018.09.001","article-title":"The experiences of people who inject drugs of skin and soft tissue infections and harm reduction: A qualitative study","volume":"65","author":"Dunleavy","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2022081503572654500_ciac344-B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-018-0262-6","article-title":"Assessing pharmacy student experience with knowledge of and attitudes towards harm reduction: Illuminating barriers to pharmacist-led harm reduction","volume":"15","author":"Mahon","year":"2018","journal-title":"Harm Reduct J"},{"key":"2022081503572654500_ciac344-B29","doi-asserted-by":"crossref","DOI":"10.31478\/201609v","article-title":"Improving access to effective care for people who have mental health and substance use disorders: a vital direction for health and health care","volume":"6","author":"Knickman","year":"2016","journal-title":"NAM Perspectives"},{"key":"2022081503572654500_ciac344-B30","volume-title":"Stuck: how vaccine rumors start and why they don\u2019t go away","author":"Larson","year":"2020"},{"key":"2022081503572654500_ciac344-B31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S2352-4642(19)30092-6","article-title":"Vaccine hesitancy: a generation at risk","volume":"3","author":"The Lancet Child & Adolescent Health","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"2022081503572654500_ciac344-B32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"key":"2022081503572654500_ciac344-B33","article-title":"Qualitative Data Analysis Software | NVivo. 2020. Available at","author":"QSR International Pty Ltd"},{"key":"2022081503572654500_ciac344-B34","doi-asserted-by":"crossref","first-page":"e0186315","DOI":"10.1371\/journal.pone.0186315","article-title":"Primary care models for treating opioid use disorders: What actually works? A systematic review","volume":"12","author":"Lagisetty","year":"2017","journal-title":"PLoS One"},{"key":"2022081503572654500_ciac344-B35","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.mayocp.2019.03.029","article-title":"Medication-assisted treatment for opioid-use disorder","volume":"94","author":"Oesterle","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2022081503572654500_ciac344-B36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13181-015-0517-5","article-title":"Pharmacotherapy of opioid addiction: \u201cPutting a real face on a false demon\u201d","volume":"12","author":"Salsitz","year":"2016","journal-title":"J Med Toxicol"},{"key":"2022081503572654500_ciac344-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12910-021-00599-2","article-title":"Pharmacy stakeholder reports on ethical and logistical considerations in anti-opioid vaccine development","volume":"22","author":"Wartenweiler","year":"2021","journal-title":"BMC Med Ethics"},{"key":"2022081503572654500_ciac344-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recommend Rep"},{"key":"2022081503572654500_ciac344-B39"},{"key":"2022081503572654500_ciac344-B40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev-neuro-080317-061522","article-title":"Endogenous and exogenous opioids in pain HHS public access","volume":"41","author":"Corder","year":"2018","journal-title":"Annu Rev Neurosci"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac344\/43734258\/ciac344.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_1\/S98\/45407556\/ciac344.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_1\/S98\/45407556\/ciac344.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T03:58:57Z","timestamp":1660535937000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/Supplement_1\/S98\/6586840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":40,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2022,5,17]]},"published-print":{"date-parts":[[2022,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac344","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,15]]},"published":{"date-parts":[[2022,5,17]]}}}